H-Index
32
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 2329-0358

Home Page

Annals of Transplantation is one of the fast-developing journals open to all scientists and fields of transplant medicine and related research. The journal is published quarterly and provides extensive coverage of the most important advances in transplantation.
Using an electronic on-line submission and peer review tracking system, Annals of Transplantation is committed to rapid review and publication. The average time... read more


Published: 2019-01-18

Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study

Laura Lladó, Ana González-Castillo, Joan Fabregat, Carme Baliellas, Emilio Ramos, Emma González-Vilatarsana, Juli Busquets, Xavier Xiol

(Liver Transplant Unit, University Hospital of Bellvitge, Barcelona, Spain)

Ann Transplant 2019; 24:36-44

DOI: 10.12659/AOT.912444


BACKGROUND: Delaying initiation of tacrolimus after liver transplantation (LT) is a potential renal-sparing strategy. We assessed safety and efficacy of delayed initiation of prolonged-release tacrolimus (PR-T) in de novo LT.
MATERIAL AND METHODS: This was a single-center, single-arm, prospective, 12-month observational study of hepatitis C virus-negative orthotopic LT patients. Immunosuppression included PR-T (initially 0.1 or 0.2 mg/kg/day) initiated on Day 3 post LT, basiliximab (20 mg) on post-transplantation Day 0 and Day 4, and intraoperative corticosteroids (500 mg). Patients received maintenance corticosteroids and mycophenolate mofetil (MMF) according to center protocol. MMF dose was adjusted according to thrombocyte count. The primary endpoint was the estimated glomerular filtration rate (eGFR) measured using the Modification of Diet in Renal Disease 4-variable formula at 12 months. Secondary endpoints included biopsy-confirmed acute rejection (BCAR) and dialysis requirement. Adverse events were recorded.
RESULTS: Sixty-nine patients (mean age 55.0 years) were included. Most patients started MMF on Day 1 (60.9%) or Day 2 (10.1%), and PR-T on Day 3 (55.1%) or Day 4 (29.0%). Mean tacrolimus trough levels (ng/mL) were: Day 7, 9.5±6.3; Day 10, 9.4±5.4; Month 1, 8.0±3.1; Month 3, 7.8±3.7; Month 6, 8.0±4.1; and Month 12, 7.2±3.1. Mean 12-month eGFR was 77.2±24.5 mL/min/1.73 m2; 72.5% of patients had eGFR >60 mL/min/1.73 m² at 12 months; 89.9% had no eGFR measurements <40 mL/min/1.73 m² during the study. Renal insufficiency (any eGFR <60 mL/min/1.73 m²) was diagnosed in 27.5% of patients; one patient required dialysis. There were no BCAR episodes; the infection rate was 36.2%, and 3 patients died. Overall, 19 patients (27.5%) developed de novo diabetes mellitus, 18 patients (26.1%) had hypercholesterolemia, and 12 patients (17.4%) had hypertriglyceridemia.
CONCLUSIONS: Quadruple therapy with delayed administration of PR-T was well tolerated and efficacious, and was associated with acceptable renal function over 12 months.

Keywords: Immunosuppression, Liver Transplantation, Prospective Studies, renal insufficiency




Published: 2019-01-15

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases in Solid Organ Graft R...


Philipp Horvath, Can Yurttas, Florian Struller, Hans Bösmüller, Ulrich M. Lauer, Silvio Nadalin, Alfred Königsrainer, Marc André Reymond

Ann Transplant 2019; 24:30-35

DOI: 10.12659/AOT.911905

Published: 2019-01-11

Kidney Transplantation in Children with Thrombosed Inferior Caval Vein – Atypical Vascular Anastomoses


Marek Szymczak, Piotr Kaliciński, Jacek Rubik, Dorota Broniszczak, Grzegorz Kowalewski, Marek Stefanowicz, Adam Kowalski, Mateusz Ciopiński, Ryszard Grenda

Ann Transplant 2019; 24:25-29

DOI: 10.12659/AOT.912657